The possibility of a new receptor blocker to angiotensin in improving control of hypertension. Non-intervention international multicenter observational prospective study of the use azilsartan medoxomil in patients with arterial hypertension and overweight or obesity in the Russian Federation and the Republic of Kazakhstan

Currently, there is evidence of a rather low efficacy of antihypertensive therapy, especially in patients with obesity and metabolic disorders that indicate the need for the search of new highly effective antihypertensive agents that have additional features to prevent destruction of target organs and cardiovascular complications. On the Russian pharmaceutical market antihypertensive drugs presents receptor blocker to angiotensin - azilsartan medoxomil (Edarbi®). The article is published design of study of the effectiveness of azilsartan medoxomil in patients with arterial hypertension and overweight or obesity in daily clinical practice of the Russian Federation and the Republic of Kazakhstan.